Drug Trial Radar · NCT01179048
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
Last checked: Nov 19, 2026Latest source record: Jul 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,341
Actual
Start
Aug 31, 2010
Primary completion
Dec 17, 2015
Study completion Dec 17, 2015
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Aug 10, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
liraglutideDrug
Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
placeboDrug
Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)Time frame: from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days)
Locations
428 sites in 33 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Alabaster, Alabama
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Huntsville, Alabama
Novo Nordisk Investigational Site
Mobile, Alabama
Novo Nordisk Investigational Site
Tempe, Arizona
Novo Nordisk Investigational Site
Little Rock, Arkansas
Novo Nordisk Investigational Site
Little Rock, Arkansas
Novo Nordisk Investigational Site
Anaheim, California
Novo Nordisk Investigational Site
Cerritos, California
Novo Nordisk Investigational Site
Escondido, California
Novo Nordisk Investigational Site
Fresno, California
Novo Nordisk Investigational Site
Los Angeles, California
Novo Nordisk Investigational Site
Los Banos, California
Novo Nordisk Investigational Site
Mission Hills, California
Novo Nordisk Investigational Site
Montclair, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
Tustin, California
Novo Nordisk Investigational Site
Walnut Creek, California
Novo Nordisk Investigational Site
Watsonville, California
Novo Nordisk Investigational Site
Aurora, Colorado
Novo Nordisk Investigational Site
Denver, Colorado
Novo Nordisk Investigational Site
Newark, Delaware
Novo Nordisk Investigational Site
Bradenton, Florida
Novo Nordisk Investigational Site
Clearwater, Florida
Novo Nordisk Investigational Site
DeLand, Florida
Novo Nordisk Investigational Site
Fort Lauderdale, Florida
Novo Nordisk Investigational Site
Kissimmee, Florida
Novo Nordisk Investigational Site
Miami, Florida
Novo Nordisk Investigational Site
Orlando, Florida
Novo Nordisk Investigational Site
St. Petersburg, Florida
Novo Nordisk Investigational Site
Tampa, Florida
Novo Nordisk Investigational Site
West Palm Beach, Florida
Novo Nordisk Investigational Site
Lawrenceville, Georgia
Novo Nordisk Investigational Site
Roswell, Georgia
Novo Nordisk Investigational Site
Chicago, Illinois
Novo Nordisk Investigational Site
Chicago, Illinois
Novo Nordisk Investigational Site
Chicago, Illinois
Novo Nordisk Investigational Site
Crystal Lake, Illinois
Novo Nordisk Investigational Site
Indianapolis, Indiana
Showing 40 of 428 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.